

Apremilast

Request details

Apremilast FOI request V3.0 – Trust

Please see the below Freedom of Information request:

- 1. Please detail the number of patients currently prescribed apremilast with a current primary diagnosis of: a) Psoriasis b) Psoriatic Arthritis?**

Psoriasis	Psoriatic Arthritis

- 2. Of the patients prescribed apremilast in the last 12 months for Psoriasis and Psoriatic Arthritis, what number of patients received treatment with targeted small molecules or biologic therapies* prior to beginning treatment with apremilast? (*See annex 1 for a list of small molecule/biologic therapies)**

Psoriasis	Psoriatic Arthritis

- 3. How many small molecule- and/or biologic-naive patients in the Trust are currently receiving a conventional non-biologic systemic therapy for Psoriasis or a conventional non-biologic disease-modifying anti-rheumatic drug (DMARD) for Psoriatic Arthritis? (e.g. methotrexate)**

Therapy	No. of patients receiving the specified therapy	
	Psoriasis	Psoriatic Arthritis
Systemic therapies		
Disease-modifying anti-rheumatic drugs (DMARDs)		

- 4. Is CCG prior-approval required for the prescribing of apremilast? Y/N. If Yes, please tick the system you use: Blueteq /Other .**

- 5. If other, what system do you use?**

- 6. Is apremilast listed individually or grouped with biologic therapies on the prior-approval form for Psoriasis and Psoriatic Arthritis?**

Psoriasis: Individually grouped Psoriatic Arthritis: Individually grouped

- 7. Please provide the wording used on the CCG's prior-approval form for the prescribing of apremilast.**

	Psoriasis	Psoriatic Arthritis
Please provide the		

wording used on the CCG's prior-approval form for the prescribing of apremilast		
--	--	--

Annex 1

abatacept (Orencia®)
adalimumab (Amgevita®, Humira®, Hyrimoz® or Imraldi®)
brodalumab (Siliq®)
certolizumab (Cimzia®)
etanercept (Benepali®)
golimumab (Simponi®)
guselkumab (Tremfya®)
infliximab (Remicade®)
ixekizumab (Taltz®)
risankizumab (Skyrizi®)
secukinumab (Cosentyx®)
tildrakizumab (Ilumya®)
tofacitinib (Xeljanz®)
ustekinumab (Stelara®)

Response Details

Questions 1, 2 & 3

In completing a search for the information requested, Cardiff and Vale University Health Board (the UHB) has confirmed that this information is not centrally recorded or collated. To retrieve the information requested would require a manual search through individual records and the UHB considers that this would exceed the limit set within regulations for responding to a request. The UHB has therefore relied upon the Section 12 exemption ('Exemption where cost of compliance exceeds appropriate limit') of the Freedom of Information Act 2000 and is refusing your request.

The UHB has estimated that to complete the work needed to respond to this request would exceed the time limit as set within regulations to respond to a Freedom of Information Act request. Under the Act there is an allowance of two and a half days, or 18 hours, to comply with a request and the cost limit set within the fees regulations for this amount of work (18 hours) is £450 for the UHB. The fees regulations specify that the cost of complying with a request must be calculated at the rate of £25 per hour.

Question 4

Is CCG prior-approval required for the prescribing of apremilast? Y/N. If Yes, please tick the system you use: Blueteq /Other .

No

Question 5

8. If other, what system do you use?

The UHB can advise that it needs to be included in formulary and local pathway. Blueteq not operational in Wales.

Question 6

Is apremilast listed individually or grouped with biologic therapies on the prior-approval form for Psoriasis and Psoriatic Arthritis? Psoriasis: Individually grouped Psoriatic Arthritis: Individually grouped

Apremilast in a standalone category in local pathways. There is no prior approval form used in Wales

Question 7

Please provide the wording used on the CCG's prior-approval form for the prescribing of apremilast.

Cardiff and Vale University Health Board does not hold this information. Clinical Commissioning Groups (CCG's) only apply to NHS Trusts in England, they do not apply to NHS Wales.

